Chemosensitization of DLBCL cells in vitro and in vivo by demethylating nucleoside analogues [methylation]

ABSTRACT: Silencing of genes that suppress the malignant phenotype by DNA methylation spurred an interest in the clinical use of epigenetic reprogramming agents. Single therapy is unlikely to be curative in the context of a heterogeneous disease such as Diffuse Large B cell Lymphomas (DLBCL). The combination of DNA demethylating drugs could increase the chance to respond to classical and new treatments. We found that DLBCL cell lines respond heterogeneously to DNA demethylating agents. In sensitive cell lines, 5-aza-2’-deoxycytidine induced a genomic signature similar to that of doxorubicin, the most important drug of the combinatorial chemotherapy regimen for DLBCL treatment. Accordingly, the combination of 5-aza-2’-deoxycytidine and doxorubicin proved to be synergistic in cell killing in vitro and

ORGANISM(S): Homo sapiens

SUBMITTER: thomas clozel 

PROVIDER: E-GEOD-31101 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress